Heme-Binding Groups in Cytochrome P450 Inhibitors: Coordination Mechanisms, Evidence Standards and Implications for CYP19A1 Ligand Design

Cytochrome P450 (CYP) enzymes are heme-thiolate monooxygenases whose inhibition can result from direct reversible axial ligation of the distal heme iron, perturbation of the axial-water environment, or metabolism-dependent heme interactions. This focused review critically examines the chemical classes used as putative heme-binding groups in small-molecule CYP inhibitors, with emphasis on imidazoles, 1,2,4-triazoles, pyridines, 1,2,3-triazoles, sulfur-containing heterocycles, hydroxamates, nitriles and isonitriles. We discuss the evidential limits of ligand-induced type II spectra, distinguish direct parent–ligand coordination from mechanism-based inactivation, and outline an evidence hierarchy integrating enzymology, UV–Vis spectroscopy, EPR-based methods, structural biology and QM/MM calculations. CYP19A1 is used as a medicinal-chemistry case study illustrating how donor identity, binding geometry, scaffold recognition and selectivity against drug-metabolising and steroidogenic CYP enzymes must be optimized concurrently. We propose practical design and validation principles for the development of selectively heme-directed CYP19A1 inhibitors.